The newly FDA-approved injection for Primary Progressive Multiple Sclerosis (PPMS) is Ocrevus Zunovo™ (ocrelizumab and hyaluronidase-ocsq).
Here's a breakdown:
Ocrevus Zunovo™ for PPMS
-
Approved Use: On September 13, 2024, the FDA approved Ocrevus Zunovo™ for treating both Relapsing Multiple Sclerosis (RMS) and Primary Progressive Multiple Sclerosis (PPMS) in adults.
-
Components: The injection contains:
- Ocrelizumab: A monoclonal antibody that targets specific immune cells.
- Hyaluronidase-ocsq: An enzyme that helps the body absorb ocrelizumab more effectively.
-
Administration: Ocrevus Zunovo™ is administered via injection.
Key Takeaways
- Ocrevus Zunovo™ is a recent advancement in the treatment of PPMS.
- The combination of ocrelizumab and hyaluronidase-ocsq aims to improve treatment efficacy.
Reference
- The information above is based on the FDA approval announcement on September 13, 2024.
